Written by Allison DeAngelis
Worldwide hope for a Covid-19 vaccine got a boost Monday after Cambridge biotech Moderna Inc. reported that its drug candidate showed positive effects in the first few patients in an early-stage study.
In the first 25 patients in a Phase 1 test, participants that received doses of Moderna’s (Nasdaq: MRNA) potential Covid-19 vaccine developed the same or greater amounts of virus-fighting antibodies than people who have recovered from the disease, according to a press release.
The effects were seen with both the low and high doses of the vaccine, known as mRNA-1273. After two doses, the 15 recipients who received the lower, 25 microgram injection showed similar levels of antibodies as seen in the blood of patients who had Covid-19 and whose bodies successfully fought the virus. The 10 subjects who received the 100 microgram dose produced even more antibodies.
Read more here.